CDK9-IN-34
CDK9-IN-34 (Compound 1b) is an inhibitor for CDK9 with an IC50 of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC50s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC50 of 145.92 μM[1].
Product Specifications
CAS Number
252725-86-3
UNSPSC
12352005
Target
CDK; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/cdk9-in-34.html
Purity
99.82
Solubility
DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
N12C=CN=CC1=NC(C3=CC=CC=C3)=C2NC4CCCCC4
Molecular Formula
C18H20N4
Molecular Weight
292.38
References & Citations
[1]Alsfouk AA, et al., Synthesis and Biological Evaluation of Imadazo[1,2-a]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus. Pharmaceuticals (Basel) . 2022 Jul 13;15 (7) :859.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNCB1260-500 1x 500 µL
Carcinoembryonic Antigen (CEA) / CD66 (C66/1260), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 